Amneal Pharmaceuticals Inc. has released its 2024 Responsible Business Report, detailing progress in environmental, social, and governance $(ESG)$ initiatives. The report outlines efforts to enhance healthcare access, promote environmental sustainability, and support workforce development. Key highlights include the introduction of a new ESG framework structured around societal impact, environmental impact, and people & practices. In 2024, Amneal filled over 162 million prescriptions in the U.S., launched 22 new generic products, and addressed drug shortages by producing over 10 critical injectable medicines. Environmental efforts included transitioning a manufacturing facility in India from coal to biomass, reducing CO₂ emissions by 1,600 tons annually, and supporting tree planting initiatives. The company also launched a global talent development framework and reported an increase in employee engagement. The full report aligns with global standards and is available on Amneal's website.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。